Market Research Logo

United States T-Cell Lymphoma Market

United States T-Cell Lymphoma Market

T-Cell Lymphoma Market
The market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach USD XX million by 2021.

Non-Hodgkin's lymphoma caused by malignant T-Cell lymphocytes represent a smaller subset (about 15% in the US) of the known types of non-Hodgkin's lymphoma - approximately 6,885 new cases are diagnosed, annually. Based on the (SEER) cancer registries, incidence rates for lymphoid neoplasms and Hodgkin lymphoma were found to be 2.09 and 2.71 per 100,000 people, respectively. Within T/NK-cell lymphoid neoplasms, incidence rates were highest for peripheral T-cell lymphoma (PTCL) (0.78), followed by mycosis fungoides/Sezary syndrome (0.54) and T/NK-cell lymphoid neoplasms, not otherwise specified (NOS) (0.49). The incidence of ATL was rare in the US (0.04). The most common PTCL subtype was PTCL-NOS (0.41), followed by anaplastic large cell lymphoma (ALCL) (0.28), cutaneous T-cell lymphoma (0.25), and angioimmunoblastic lymphoma (0.10). The remaining PTCL sub-types (subcutaneous panniculitis-like T-cell lymphoma, hepatosplenic T-cell lymphoma, enteropathy-type T-cell lymphoma) were rare and had incidence rates of 0.01 per 100,000 persons.

Global T-Cell Lymphoma - Market Dynamics

The report details several factors driving and restraining the market, some of which are discussed below.

Drivers

Rising healthcare expenditure
Numerous chemotherapy agents driving the market
Reimbursement policies covering cancer therapies
Restraints

Poor incidence rate
Low awareness about lymphoma and treatment options
Adverse side effects of the therapies
Market Segmentation

The global T-cell lymphoma market has been segmented by type of disease into extranodal T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, and angioimmunoblastic T-cell lymphoma. The market, by treatment type, is divided into radiotherapy, chemotherapy, stem cell transplantation, and surgery. The chemotherapy treatment includes major drugs such as Bexarotene (Targretin), Denileukin Diftitox (Ontak), Romidepsin (Istodax), And Vorinostat (Zolinza), among many others. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.

Some of the key players in the market are:

Actelion Pharmaceuticals
Allos Therapeutics
Astellas Pharma
Bristol-Myers Squibb
Celgene Corporation
Eisai
Genmab
Galderma
Inovio Pharmaceuticals
Johnson & Johnson Pharmaceutical Research & Development
Novartis
Onyx Pharmaceuticals
Roche
Seattle Genetics
Others
What the Report Offers

Market definition, along with identification of key drivers and restraints for the market.
Market analysis with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.
An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.


1. INTRODUCTION
1.1 Study Deliveratives
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
1.7 Report Description
2. RESEARCH METHODOLOGY
2.1 Introduction
2.2 Analysis Methodology
2.3 Study timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW AND INDUSTRY TRENDS
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porters Five Force Analysis
5.3.1 Bargaining Power Of Suppliers
5.3.2 Bargaining Power Of Buyers
5.3.3 Degree Of Competition
5.3.4 Threat Of Substitution
5.3.5 Threat Of New Entrants
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 Market Drivers
6.1.1 Rising Healthcare Expenditure
6.1.2 Numerous Number of Chemotherapy Agents Driving the Market
6.1.3 Reimbursement Policies Covering Cancer Therapies
6.2 Market Restraints
6.2.1 Poor Incidence Rate
6.2.2 Low Awareness About Lymphoma and Treatment Options
6.2.3 Adverse Side Effects of the Therapies
6.3 Market Opportunities
6.4 Key Challenges
7. Global T-Cell Lymphoma Market - Segmentation
7.1 By Type of Lymphoma
7.1.1 Extranodal T Cell Lymphoma
7.1.2 Cutaneous T Cell Lymphomas
7.1.3 Anaplastic Large Cell Lymphoma
7.1.4 Angioimmunoblastic T Cell Lymphoma
7.1.5 Others
7.2 By Therapy Type
7.2.1 Radiotherapy
7.2.2 Chemotherapy
7.2.2.1 Belinostat (Beleodaq)
7.2.2.2 Denileukin Diftitox (ONTAK)
7.2.2.3 Mogamulizumab (Poteligeo)
7.2.2.4 Brentuximab Vedotin (Adcetris)
7.2.2.5 Pralatrexate (Difolta/Folotyn)
7.2.2.6 Interferon gamma 1a Biosimilar (Imunomax-γ)
7.2.2.7 Nelarabine (Arranon/ Atriance)
7.2.2.8 Vorinostat (Zolinza)
7.2.2.9 Romidepsin (Istodax)
7.2.2.10 Bexarotene Topical (Targretin Gel)
7.2.2.11 Bexarotene Oral (Targretin Oral)
7.2.2.12 Chlormethine (Ledaga/Valchlor)
7.2.2.13 Methoxsalen Solution (UVADEX)
7.2.2.14 Mogamulizumab Companion Diagnostics (Poteligeo Test FCM/IHC)
7.2.2.15 Interferon alpha-2a (Roferon-A)
7.2.3 Stem Cell Transplantation
7.2.4 Surgery
7.2.5 Other
7.3 By Development/ Marker
7.3.1 Terminal Deoxynucleotidyl Transferase
7.3.2 CD30
7.3.3 Other
8. Global T-Cell Lymphoma Market - Regional Shares and Forecast
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 UK
8.2.3 France
8.2.4 Italy
8.2.5 Spain & Portugal
8.2.6 Scandinavia
8.2.7 Benelux
8.2.8 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 The Middle East and Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of the Middle East and Africa
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Actelion Pharmaceuticals
10.2 Allos Therapeutics
10.3 Astellas Pharma
10.4 BioCryst Pharmaceuticals
10.5 Bristol-Myers Squibb
10.6 Chipscreen Biosciences
10.7 Celgene Corporation
10.8 Eisai
10.9 Genmab
10.10 Galderma
10.11 Inovio Pharmaceuticals
10.12 Johnson & Johnson Pharmaceutical Research & Development
10.13 Karyopharm Therapeutics
10.14 Kyowa Hakko Kirin
10.15 Nippon Kayaku
10.16 Novartis
10.17 Neumedicines
10.18 Onyx Pharmaceuticals
10.19 Roche
10.20 Seattle Genetics
10.21 Shionogi
10.22 Soligenix
10.23 TetraLogic Pharmaceuticals
10.24 ZIOPHARM Oncology
10.25 Others
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report